AMAG Pharmaceuticals Provides Update on FDA’s Proposal Regarding Makena® (Hydroxyprogesterone Caproate Injection)
The product remains on the market AMAG has 15 days to respond to the FDA AMAG continues to expect its recently announced tender offer and merger to close in November 2020 WALTHAM, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ …